About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

It's nothing less than than a bl**dy disgrace driver!, how the flock can we pay footballers more money for a weeks pay than erx can raise for a years research ?

Not yet finalised - EiRx has "agreed in principle a funding package designed to provide working capital to fund the Company until at least 31 December 2008", but I can't see them not carrying on. Makes me think that there must be a future extending beyond this year, which makes me further think that there is a value in their portfolio greater than the share price indicates. I am hanging on for another roller coaster year!

Massive dilution.

Shares/warrant/notes issued at 0.015p, a fraction of the market price.

4,000,000,000 new shares to be issued, plus loan notes which will dilute even more when converted.

Existing shareholders effectively being wiped out.

Does look a bit crap on the face of it.

Hmmmmm, quite. Still, life in the old dog yet; might be worth picking up a few million when the sp hits the bottom, which may not be long now!

A few million at 0.01p. That'll be 200 worth then?

Only if you like throwing your money away imo.

I look upon it as an investment in the future Relishing; the future of what though remains to be seen!!

Well some one just bought 2's worth that should raise the sp.

OFFICIAL CORRECTION EiRx Therapeutics gets funding package for drug development
AFX


(Company corrects number of shares placed to 4 bln not 4 mln)

LONDON (Thomson Financial) - EiRx Therapeutics PLC said it has put in place a funding package which it believes is sufficent and will allow it to advance its drug development programme over the next 12 months.

The funding package comprises a placing of shares for cash, the issue of convertible loan stock and an increase in the secured bank facility.

The company said it has placed a total of 4 bln shares at a price of 0.015 pence per share to raise 600,000 stg. Of this amount, 170,125 stg is as a debt for equity swap. Subscribers under the placing will be granted one warrant for every three shares subscribed, subject to shareholder consent. Each warrant is convertible at a price of 0.015 pence per share.

EiRx added that Billam AG has agreed to make available a further 300,000 stg of funding from September 2008 through zero coupon non-redeemable convertible loan stock, convertible at the current placing price of 0.015p per share.

Billam has also agreed to guarantee additional secured bank borrowings of up to 350,000 stg to replace the existing facility of 200,000 stg as announced on Nov 8, 2007, EiRx said.



tf.TFN-Europe_newsdesk@thomson.com

370m sell at .0001 Not good.

Deals of 137,500,000 & 126,200,00 at the upper end today and 2 x 100 at the lower end :o)

A lot of buying and dumping on ERX I'm staying clear.

From the other side.

The very large trades you see going through are the placed shares bought at

.00015 by the participating brokers, being sold on to buyers at .0004, they are

being sold today but will not be eligible to trade until Mon. the 25th Feb.

same as you driver, staying well clear ...still a way to go here me thinks !

200m @ 1p ????

This is the first time I've seen one of these!


London Stock Exchange Plc
10 Paternoster Square
26 February 2008 London EC4M 7LS
Telephone +44 (0)20 7797 1000

www.londonstockexchange.com


For the attention of the
chairman/senior partner/compliance officer,
all member firms N02/08


STOCK EXCHANGE NOTICE

NOTIFICATION - EIRX THERAPEUTICS PLC - ISIN GB00B0XQBS97


1. Further to the AIM Notice published at 7.30am on 25 February 2008
(RNS Number 6334O) and subsequent investigation, the Financial Services
Authority ('FSA') has instructed Euroclear UK and Ireland to delay
settlement of all trades in EIRx Therapeutics PLC for 24 hours.

2. A further Notice will be issued in due course.

3. Any queries on this Notice should be addressed to Tim Rowe, Trading
Services, telephone +44 20 7797 3468 (STX 33468)
email:
trowe@londonstockexchange.com.

Nick Bayley
Head of Trading Services

This Stock Exchange Notice will be available on the website at
http://www.londonstockexchange.com/en-gb/products/membershiptrading/rulesreg/
stockexnotices/stockexchangenotices2008.htm

Something very dodgy going on with this share by the look of it?

AS I said on the 21st, Buying and dumping on ERX I'm staying clear

hmm !!! agree driver something not right here !!

It will be ineteresting to see what this is all about!!



TEMPORARY SUSPENSION OF TRADING ON AIM


EIRX THERAPEUTICS PLC



Due to the continuation of the situation notified by the London Stock Exchange
('the Exchange') in the announcement on 25 February 2008 (RNS Number 6334O) and
the continuing delay in settlement of all trades in the Company's AIM
securities, trading on AIM for the under-mentioned securities has been
temporarily suspended with immediate effect.


Ordinary Shares of 0.001p each (B0XQBS9)(GB00B0XQBS97)
fully paid



As previously stated on 25 February 2008, the Exchange has no reason to believe
that this matter involves or affects the Company.

The Exchange will make a further announcement as soon as possible.


If you have any queries relating to the above, please contact AIM Regulation at
the London Stock Exchange on 020 7797 4154



AIM Regulation

Ref: AIMNOT122




This information is provided by RNS
The company news service from the London Stock Exchange